证券代码：002570 证券简称：贝因美 公告编号：2026-004 贝因美股份有限公司 关于向银行申请资产抵押贷款的公告 贝因美股份有限公司（以下简称"公司"或"本公司"）于 2026 年 1 月 9 日召开第九届董事会第十四次会议，审议通过《关于向银行申请资产抵押贷款的 议案》。现将具体事项公告如下： 一、本次拟申请资产抵押贷款的基本情况 为满足公司日常生产经营的资金需求，公司拟使用本公司及子公司资产向银 行申请抵押贷款。期限自银行贷款划至公司银行账户之日起计算。申请贷款的银 行、贷款利率等条款以公司及子公司最终与银行签订的合同为准。 本次拟申请抵押贷款为公司本年度正常办理银行贷款所需，对公司生产经营 不存在不利影响，公司董事会提请股东会授权公司管理层办理贷款事宜。 本议案尚需提交公司股东会审议。 二、拟抵押资产的概况 公司本次拟用于抵押的资产为自有土地、房屋、建筑物以及子公司所持土地、 厂房、建筑物、机器设备等，上述资产截至 2025 年 12 月 31 日的资产净值合计 为 9.87 亿元（未经审计），占最近一期经审计总资产的 24.42%。本年度申请贷款 的实际金额、期限以银行的最终审批结果为准。 ...

证券代码：002570 证券简称：贝因美 公告编号：2026-003 贝因美股份有限公司 关于公司向银行申请综合授信额度的公告 注：实际金额、期限以银行的最终审批结果为准。 公司董事会提请股东会授权公司董事长代表公司签署上述授信额度内的一 切与授信有关的合同、协议、凭证等法律文件，由此产生的法律、经济责任全部 由本公司承担。此项授权自股东会审议通过之日起一年有效。 本次申请银行综合授信额度事项尚需提交公司股东会审议。如根据银行最终 审批结果，授信事项涉及抵押、担保等，应根据抵押、担保等具体情况，按照《公 司章程》规定的审批权限履行相应程序后方可实施。 二、备查文件 1、第九届董事会第十四次会议决议； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"或"本公司"）于 2026 年 1 月 9 日召开第九届董事会第十四次会议，审议通过了《关于公司向银行申请综合授信 额度的议案》。现将具体事项公告如下： 一、本次申请授信的基本情况 公司根据 2026 年度生产经营需要，本年拟向银行申请借款、开立银行承兑 汇票等总计不超过 29.5 ...

证券代码：002570 证券简称：贝因美 公告编号：2026-007 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 一、召开会议的基本情况 1、股东会届次：2026 年第一次临时股东会 2、股东会的召集人：董事会 贝因美股份有限公司 关于召开 2026 年第一次临时股东会的通知 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股票上市规则》《深圳证 券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律、行政法规、部门规章、规 范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2026 年 01 月 26 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2026 年 01 月 26 日 9:15- 9:25，9:30-11:30，13:00-15:00；通过深圳证券交易所互联网投票系统投票的具体时间为 2026 年 01 月 26 日 9:15 至 15:00 的任意时间。 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2026 年 01 月 ...

证券代码：002570 证券简称：贝因美 公告编号：2026-002 贝因美股份有限公司 第九届董事会第十四次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 二、董事会会议审议情况 1、审议通过了《关于公司向银行申请综合授信额度的议案》。 同意公司向银行申请总计不超过 29.50 亿元的授信额度，实际金额、期限以 银行的最终审批结果为准，自股东会审议通过后一年内有效。授信期内，授信额 度可循环使用。同时提请股东会授权公司董事长代表公司签署上述授信额度内的 一切与授信有关的合同、协议、凭证等法律文件。 议案具体内容详见公司同日披露于指定信息披露媒体及巨潮资讯网 （http://www.cninfo.com.cn）上的《关于公司向银行申请综合授信额度的公告》 （公告编号：2026-003）。 本议案已经公司董事会审计委员会确认，并同意提交董事会审议。 表决结果：同意 8 票，反对 0 票，弃权 0 票。议案审议通过。 一、董事会会议召开情况 1、本次董事会由贝因美股份有限公司（以下简称"公司"）董事长谢宏先 生召集和主持，会议通知于 2025 年 1 ...

Group 1 - The article discusses the importance of infant complementary foods, which include various types of food beyond breast milk, such as juices, purees, and solid foods, emphasizing the need for balanced nutrition during the critical growth period of infants [2] - The report titled "2026-2032 China Infant Formula Market Panorama Survey and Investment Potential Analysis" consists of eleven chapters, covering the market development environment, operational status, competitive landscape, key enterprise analysis, and future trends in the infant food industry [2] - The report serves as a crucial tool for understanding the infant food industry and for potential investors looking to enter this market [2] Group 2 - The research data is primarily sourced from national statistics, customs data, survey data, and various market monitoring databases, ensuring a comprehensive analysis of the infant formula industry [3] - The report includes an overview of the infant formula industry, its development environment, and the current operational status, along with a competitive analysis of the market [3][4] - The analysis covers the macroeconomic environment in China, including population birth rates and the implications for the infant formula market from 2021 to 2025 [4] Group 3 - The report highlights the competitive landscape of the infant formula market, noting the increasing competition from foreign brands and the strategies domestic brands must adopt to maintain market share [5][6] - It discusses the significance of product quality and brand value as key factors for success in the high-end infant formula market, which is expected to see significant growth [10][11] - The report predicts that the infant formula market will experience a shift towards high-quality, natural products, with an emphasis on organic options [11]

Core Insights - The probiotics industry is transitioning towards evidence-based medicine, with the global market for probiotic supplements expected to reach $9.8 billion by 2025, driven by high-activity formulations that cater to specific gut issues in older adults and adults, with an annual growth rate exceeding 27.3% [2][3] - Consumer awareness has shifted from trusting functional claims to prioritizing clinical data and strain compatibility, leading to increased demand for probiotics supported by clear evidence [2][3] Industry Development - The probiotics market is evolving to focus on clinical evidence and user feedback, addressing the needs of older adults and adults facing gut health issues due to lifestyle and physiological changes [2][3] - The demand for high-activity probiotic products that are clinically validated is on the rise, particularly among older adults suffering from chronic constipation and digestive issues [2][3] Scientific Evaluation Standards - A seven-dimensional evaluation system has been established to assess probiotics, focusing on composition, bioavailability, safety certifications, strain traceability, active ingredient protection, clinical evidence, and consumer feedback consistency [3][4] - Key metrics include survival rates in simulated gastric conditions, safety certifications from national and international authorities, and clinical trial results demonstrating efficacy in improving gut health [3][4][5] Brand Evaluation - Eight brands were selected from 32 global probiotic brands based on strict adherence to the seven-dimensional evaluation criteria, representing various technological approaches [4] - The top brand, Plant Formula Probiotic Powder, is recognized for its targeted approach to gut health in older adults and adults, addressing specific issues such as constipation and digestive disorders [5][6] Product Features - Plant Formula Probiotic Powder contains 30 strains and is designed to meet the unique gut health needs of older adults and adults, ensuring effective colonization and addressing multiple digestive issues [5][6][7] - The product's formulation adheres to strict standards, including no added sugars or preservatives, making it suitable for long-term use among individuals with chronic health conditions [6][8] Clinical Evidence - A multi-center clinical study involving 6,201 participants showed significant improvements in gut health metrics, including a 71.4% increase in gut microbiome diversity and a 94.4% relief rate for digestive discomfort among older adults [11] - The product has been validated for its effectiveness in addressing specific gut health issues, with high rates of improvement reported in clinical trials [11][12] Consumer Feedback - High customer satisfaction is reflected in a 98.6% repurchase rate and minimal negative feedback, with users highlighting the product's transparency and effectiveness in addressing gut health issues [12][13] - The product has gained recognition in major hospitals, becoming a preferred choice for managing digestive health in older adults and adults [12][13] Future Outlook - The company aims to enhance its probiotic offerings by focusing on targeted delivery technologies and expanding its research collaborations, with plans to transition probiotics from dietary supplements to precise gut health interventions for older adults and adults [22][23]

格隆汇1月5日丨贝因美（维权）(002570.SZ)公布，截至2025年12月31日，公司通过股份回购专用证券 账户以集中竞价交易方式累计回购公司股份1773.03万股，占公司总股本的1.6416%，最高成交价为7.21 元/股，最低成交价为6.01元/股，成交总金额为111,728,763.92元(不含交易费用)。 ...

（记者 曾健辉） 每经头条（nbdtoutiao）——秒光！1499元飞天茅台上线即空，i茅台App冲上苹果购物榜第一，10万用 户已下单！经销商同价做回馈，1000箱很快卖完 每经AI快讯，贝因美1月5日晚间发布公告称，截至2025年12月31日，公司通过股份回购专用证券账户 以集中竞价交易方式累计回购公司股份约1773万股，占公司总股本的1.6416%，最高成交价为7.21元/ 股，最低成交价为6.01元/股，成交总金额约为1.12亿元。 ...

证券代码：002570 证券简称：贝因美 公告编号：2026-001 一、回购股份的进展情况 截至 2025 年 12 月 31 日，公司通过股份回购专用证券账户以集中竞价交易 方式累计回购公司股份 17,730,254 股，占公司总股本的 1.6416%，最高成交价为 7.21 元/股，最低成交价为 6.01 元/股，成交总金额为 111,728,763.92 元（不含交 易费用）。 公司股份回购的实施符合公司回购方案及相关法律法规的要求。 二、其它说明 公司回购股份的时间、回购股份价格及集中竞价交易的委托时间段符合《上 贝因美股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 贝因美股份有限公司（以下简称"公司"）于 2025 年 4 月 29 日召开的第九 届董事会第九次会议审议通过了《关于回购公司股份方案的议案》，公司拟以集 中竞价交易方式回购公司 A 股股票，用于公司未来实施的股权激励或员工持股 计划。本次回购金额不超过人民币 3 亿元（含），不低于人民币 1.5 亿元（含）， 回购价格不超过 9.06 元/股（ ...

Core Viewpoint - The company plans to repurchase A-shares through centralized bidding, with a total amount ranging from 150 million to 300 million yuan, aimed at employee stock ownership plans or equity incentives [1] Group 1: Repurchase Details - The repurchase price will not exceed 9.06 yuan per share, with an expected total of 33.11 million shares to be repurchased, accounting for 3.07% of the total share capital [1] - As of the end of 2025, the company has cumulatively repurchased 17.73 million shares, representing 1.6416% of the total share capital, with a total transaction amount of 112 million yuan [1] - The highest transaction price recorded was 7.21 yuan per share, while the lowest was 6.01 yuan per share [1] Group 2: Future Plans - The company will continue to implement the repurchase plan and will disclose information in a timely manner [1]